Labcorp: 3 Key Takeaways for Long-Term Investors
On its third-quarter 2026 earnings call, held on Oct. 28, 2026, Labcorp (NYSE:LH) announced 7% revenue growth to $3.8 billion alongside raised full-year guidance. Enterprise profit expansion and solid organic demand show how scale keeps driving long-term earnings leverage. Three things management said stand out. Proposed fee schedule changes under PAMA, the Protecting Access to Medicare Act, will lower Medicare reimbursement rates across hundreds of tests starting in 2027. Management plans to counter the $125 million hit through volume growth, biopharma demand, and cost efficiencies. High-growth specialty areas like oncology and neurology carry higher margins and pull routine volume along with them. Physicians ordering specialized diagnostic panels routinely send companion core testing to the same laboratory provider. Continue reading